Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Westin

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Blood Advances|January 10, 2022
Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvementSerkan Akin, Chitra Hosing, Issa Khouri, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomographyChelsea C Pinnix, Bouthaina Dabaja, Mohamed Amin Ahmed, et al.
JAMA Network Open|April 7, 2025
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T TherapyJames P Long, Rishab Prakash, Paul Edelkamp, et al.
Blood Advances|June 14, 2018
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCLChelsea C Pinnix, Andrea K Ng, Bouthaina S Dabaja, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Critical Care Medicine|July 14, 2021
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter StudyCristina Gutierrez, Anne Rain T Brown, Heather P May, et al.
Critical Care Medicine|December 30, 2025
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICUPrabalini Rajendram, R Scott Stephens, Anne Rain T Brown, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 15, 2019
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with LymphomaNeeraj Y Saini, Rima M Saliba, Gabriela Rondon, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Blood Advances|January 10, 2022
Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvementSerkan Akin, Chitra Hosing, Issa Khouri, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomographyChelsea C Pinnix, Bouthaina Dabaja, Mohamed Amin Ahmed, et al.
JAMA Network Open|April 7, 2025
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T TherapyJames P Long, Rishab Prakash, Paul Edelkamp, et al.
Blood Advances|June 14, 2018
Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCLChelsea C Pinnix, Andrea K Ng, Bouthaina S Dabaja, et al.
American Journal of Hematology|March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapyMatthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Critical Care Medicine|July 14, 2021
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter StudyCristina Gutierrez, Anne Rain T Brown, Heather P May, et al.
Critical Care Medicine|December 30, 2025
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICUPrabalini Rajendram, R Scott Stephens, Anne Rain T Brown, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 15, 2019
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with LymphomaNeeraj Y Saini, Rima M Saliba, Gabriela Rondon, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.
Pageof 10